2020 has been a difficult year for everyone. However, despite the many challenges, we can also look back on some milestone achievements. In our latest newsletter, we review some of our major highlights. Click the link to read our newsletter: http://bit.ly/3njT6nQ
Would you like to receive our next newsletter in your email? You can subscribe here: https://www.tricals.org/subscribe-to-our-newsletter/
We look forward to the new year in which we will undoubtedly achieve even more together. Together we will build our highway towards new therapies for ALS.
Noticias relacionadas
European Commission approves Tofersen as treatment for ALS-SOD1
The European Commission has approved the drug QALSODY, better known as Tofersen. […]
Amylyx terminates open-label extension of the PHOENIX study
The pharmaceutical company Amylyx has announced that they will terminate the open-label […]
Meet the centre - Torino ALS Center (University of Torino)
The TRICALS consortium currently consists of more than 40 centers across Europe. […]
Amylyx withdraws RELYVRIO/AMX0035 from U.S. and Canadian markets
Yesterday, the pharmaceutical company Amylyx announced that they are withdrawing the drug […]